Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb;5(1):51-62.
doi: 10.3978/j.issn.2223-4683.2015.12.07.

Medical management of neurogenic bladder with oral therapy

Anne P Cameron  1
Affiliations
Review

Medical management of neurogenic bladder with oral therapy

Anne P Cameron. Transl Androl Urol. 2016 Feb.

Abstract

This is a review of the most current literature on medical management of the neurogenic bladder (NGB) to treat detrusor overactivity (DO), improve bladder compliance and treat urinary incontinence. The use of antimuscarinics, alpha blockers, tricyclic antidepressants, desmopressin and mirabegron will be discussed along with combination therapy to improve efficacy. These medical therapies will be the focus of this review with surgical therapy and botulinum toxin injections being the subject of other articles in this series.

Keywords: Neurogenic bladder (NGB); adrenergic alpha blockers; antimuscarinics; desmopressin; imipramine; mirabegron.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flowchart of pharmacologic treatment of neurogenic bladder based on symptoms and urodynamic findings. *, storage symptoms = urgency, frequency, urgency incontinence and nocturia; **, recommended starting dose 10 mg po BID-TID.
See this image and copyright information in PMC

References

    1. Cameron AP, Wallner LP, Tate DG, et al. Bladder management after spinal cord injury in the United States 1972 to 2005. J Urol 2010;184:213-7. - PubMed
    1. Nortvedt MW, Riise T, Frugård J, et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Mult Scler 2007;13:106-12. - PubMed
    1. Nicholas RS, Friede T, Hollis S, et al. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev 2009;(1):CD004193. - PubMed
    1. Torre M, Guida E, Bisio G, et al. Risk factors for renal function impairment in a series of 502 patients born with spinal dysraphisms. J Pediatr Urol 2011;7:39-43. - PubMed
    1. Gerridzen RG, Thijssen AM, Dehoux E. Risk factors for upper tract deterioration in chronic spinal cord injury patients. J Urol 1992;147:416-8. - PubMed